lactation – Page 6 – Communicable Diseases Research

Equity in coronavirus disease 2019 vaccine development and deployment

Article

Published on 2021-01-152023-07-01
Journal: American journal of obstetrics and gynecology [Category] SARS,

Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial

일차 진료 환경(LIBERTY)에서 Covid-19 감염 성인 환자 치료에 사용되는 하이드록시클로로퀸: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-112022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 addition addressed administration Adult patients adverse event adverse events AEs age all-cause hospitalization Antibody Response Anxiety Anxiety Disorder ARMS association Biomarker blinded Blinding Blood BMI capture Care changes changes in Characteristics clinical trial concentrations concomitant medications conducted Contact Course COVID-19 COVID-19 infection COVID-19-related symptoms criteria death deleting Demographic variables diabetes Diabetes Mellitus disease dissemination double-blind Effect element enrolment enzyme EudraCT evaluate exclusion expected exploratory exploratory endpoint Exploratory endpoints female Formulation GAD-7 Generalized Generalized Anxiety Disorder Genetic variation HCQ Health care HLA haplotypes hospital Hospitalization hospitalizations Hydroxychloroquine Hypothesis identify include Inclusion independent individual Infection information intensive care unit lactation masking mental health Meta-analysis Mortality Nasopharyngeal swab nasopharyngeal swab sample Nasopharyngeal swab samples number number of deaths objective onset of symptom open care outcome Outpatient outpatients parallel-group participant Patient patient data PCR test PCR testing PCR-confirmed Placebo placebo-controlled post-hoc predict Pregnancy presenting primary care primary endpoint protocol public health public health care randomised randomised controlled trial randomization list Randomized Randomly receive recruitment reduce Registered Regulation repeated reported respiratory respiratory distress respiratory rate response risk room air SAEs Sample size SARS-CoV-2 SARS-CoV-2 PCR test SARS-CoV-2 viral shedding Satakunta secondary endpoint Secondary endpoints Secondary objectives serious AE serum Seven severe pneumonia severity specific treatment status study participant Study participants study population Study protocol subgroup analysis subject supplementary material Suspected Symptom Symptoms technology test result therapeutic potential Tolerability treated Treatment treatment allocation treatment arm Trial Trial registration twice a day type 1 or type 2 Uppsala variable Viral was performed website Well-being
[DOI] 10.1186/s13063-020-04989-6 PMC 바로가기 [Article Type] Letter

Pregnant people deserve the protection offered by SARS-CoV-2 vaccines

Comment

Published on 2021-01-082023-07-12
Journal: Vaccine [Category] SARS,

[키워드] COVID-19 fetal High-risk patients lactation maternal immunization Neonatal Pregnancy research and development SARS-CoV-2 vaccination
[DOI] 10.1016/j.vaccine.2020.12.007 PMC 바로가기 [Article Type] Comment

Maintaining human milk bank services throughout the COVID‐19 pandemic: A global response

Original Article

Published on 2021-01-062022-10-30
Journal: Maternal & Child Nutrition [Category] COVID-19, MERS, SARS,

Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial

COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-062022-09-10
Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제,

[키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter

Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial

중증 급성 호흡기 증후군이 있는 COVID-19 환자 관리에 대한 중국 전통 의학 Maxingshigan-Weijing의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-12-232022-08-31
Journal: Trials [Category] MERS, SARS, 임상, 치료제,

[키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus addition administration Affiliated Hospital age allergic allergies anorexia anti-bacterial Anti-viral anticipated Anxiety Arm asked Asymptomatic automatically aversion blinded Blinding Blood tinged blood tinged sputum both groups Care carried center checklist Chenpi chest pain chest X-ray Chinese Chinese Clinical Trial Registry Chinese herbal medicines clinical clinical symptom clinical trials clinically Cold comparator Patients composed control group Controlled trial coronavirus cough COVID-19 COVID-19 patient criteria critical patient critical patients defined diarrhea disease Diseases dissemination distension Dizziness dry mouth dysphoria effective Efficacy element Eligible patients ephedra exclusion criteria expectoration female Fever Follow-up four-point scale Gypsum H1N1 H1N1 influenza headache hematopoietic system Herba Ephedra herbal medicine hospital IBM IBM Corp IMPROVE improvement in both group include Inclusion inclusion and exclusion criteria inclusion criteria individual Influenza Informed consent Inpatient Insomnia Kaplan-Meier method kidney Kidney function lactation less liver log-rank test malaise male management Maxingshigan-weijing mechanical ventilation Medicine Melon Mild mild clinical symptoms multicenter multiple organ failure muscular nasal nasal obstruction nausea nausea and vomiting negative test nucleic acid number objective open Open-label oral administration outcome participant Patient patients Peach pharyngalgia Pneumonia positive Pregnancy previous study Primary outcome Professor proportion protocol Radix random random allocation random number generator randomisation randomised Randomized Randomized controlled trial randomly divided receive recruited registry reported researcher respiratory Respiratory failure respiratory symptom Sample size SARS-CoV-2 SARS-CoV-2 nucleic acid Scoring second secondary Secondary outcomes Semen sequence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 severity Shock Shortness of breath statistical analysis Statistical power Statistics status Study protocol suffering supplementary material supportive care survival survival time sweating Symptom symptomatic Symptoms System TCM temperature test results the median therapy total score Traditional Traditional Chinese medicine treated Treatment trial protocol Trial registration Trichosanthe Trichosanthes Kirilowii university USA Version virus pneumonia vomiting website wheezing Winter Withdrawal
[DOI] 10.1186/s13063-020-04970-3 PMC 바로가기 [Article Type] Letter

Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy

Article

Published on 2020-11-262023-07-12
Journal: Journal of perinatal medicine [Category] SARS,

[키워드] COVID-19 lactation Pregnancy Teratology toxicology
[DOI] 10.1515/jpm-2020-0339

Antiviral drugs for influenza for 2020-2021

Article

Published on 2020-11-022023-07-12
Journal: The Medical letter on drugs and therapeutics [Category] SARS,

The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial

COVID-19 환자의 치료 보조제로 커큐민을 함유한 나노 미셀의 임상 효과 및 치료 후 면역 반응 균형 변화: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-10-222022-08-13
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 accompany addition allergy assigned balance Bandar Abbas bedtime blind Blinding both groups breakfast Capsule change Characteristics chronic chronic obstructive pulmonary disease clinical Clinical effect clinical examination clinical examinations clinical symptom clinical trial clinical trials Comorbidities Comorbidity company comparator Complete computer conducted congestive heart failure control group COVID-19 COVID-19 patient COVID-19 patients Curcumin Cytokines digit digits dinner dissemination Effectiveness element evaluate evaluated expected expression filtration filtration rate FOXP3 gallstone gastritis GATA Gender Gene Expression glomerular filtration rate heart failure history IFN-γ IL-17 IL-4 immune response immune responses in both group inclusion criteria Inflammatory marker inflammatory markers information Interleukins intervention group Iran kPa Laboratory laboratory findings laboratory technician laboratory technicians lactation less liver liver failure Lymphocytes number Nurses objective Obstructive obstructive pulmonary disease outcome PaO2 parallel group participant Participation Patient patients patients with COVID-19 per day performed Peripheral blood physician Placebo placebo group placebo-controlled positive COVID-19 post treatment Pregnancy protocol pulmonary disease random randomisation randomised randomised controlled trial randomization Randomized randomized clinical trial Randomly real time PCR recorded recruitment Registered registry Regulatory renal renal failure routine standard treatment Sample size sealed selected serum cytokine serum cytokines Serum level serum parameter serum parameters shift single-center statisticians Study protocol T helper TGF-β the placebo group therapeutic Treatment Trial Trial registration ventilator Version website written consent
[DOI] 10.1186/s13063-020-04824-y PMC 바로가기 [Article Type] Letter

Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-162022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Administered administration Admission age allergy anti-IL6 anti-IL6 inhibitor antibody approved ARDS assigned AST/ALT authority baseline Blinding block Blood Brescia caused changed clinical clinical follow-up Clinical practice clinical trial concealed conducted consequence control arm control group Corticosteroids COVID COVID-19 COVID-19 infected patient COVID-19 infected patients COVID-19 patients CRP cytokine release death dissemination dose early intervention early treatment eCRF effective Efficacy and safety element elements elevated End end point EudraCT evaluate Evidence experimental arm Face mask Final Follow-up hospital Hospitalized hospitalized patients hyperinflammation Hyperinflammatory syndrome hypersensitivity Hypothesis ICU ICU admission IL-6 IL6 immunosuppressive in some inflammatory markers inflammatory parameter inhibitor initial Injury interstitial pneumonia Intervention lactation LDH life-threatening Local lymphopenia mechanical ventilation Methylprednisolone multi organ failure nasal neutropenia Non-invasive number objective open label Open-label outcome Oxygen requirement Parallel Arm participant pathogen Patient patients performed Pneumonia positive RT-PCR Pregnancy PROC produced progression proportion protocol protocols provided pulmonary infiltrate Radiographic randomised randomised controlled trial randomization Randomly RCT receive Registration reported rescued Respiratory failure risk risk factor Sample size sarilumab SARS-CoV SARS-CoV-2 SAS Sepsis Serum ferritin severe COVID-19 severe COVID-19 disease severe interstitial pneumonia severe respiratory failure Spain Spanish SpO2 Standard Standard of care study drug Study protocol supplemental oxygen therapeutic therapeutic intervention therapy Treatment treatment arm Treatment outcome Trial ULN use of corticosteroid Viral pneumonia virus website worsening
[DOI] 10.1186/s13063-020-04633-3 PMC 바로가기 [Article Type] Letter